165 citations
,
June 2007 in “European Journal of Cell Biology”
Hair follicle stemcells are key for hair and skin regeneration, can be reprogrammed, and have potential therapeutic uses, but also carry a risk of cancer.
Hair follicle stemcells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
Stemcellhair transplants use stemcells from fat tissue to reactivate inactive hair follicles, but results are inconsistent and not widely shared. Traditional treatments like finasteride and minoxidil often show better results.
Adipose-derived stemcells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stemcells with ATP for males and medium dose stemcells with non-liposomal ATP for females.
Hair regrowth treatments, including stemcell injections, are discussed, with skepticism about their effectiveness compared to Minoxidil and finasteride. Derma stamping is mentioned as effective when used with Minoxidil, finasteride, and dutasteride.